Abstract:Abstract Purpose Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. A genetically engineered brainstem glioma model harboring the recurrent DIPG mutation, ACVR1-G328V (mACVR1), was developed for testing an immune-stimulatory gene therapy. Experimental Design We utilized the Sleeping Beauty transposase system to generate an endogenous mouse model of mACVR1 brainstem glioma. Histology was used to characterize and validate the model. We performed RNAseq analysis on neurospheres (NS) harboring mACVR1. mACVR1 NS were implanted into the pons of immune competent mice to test the therapeutic efficacy and toxicity of immune stimulatory gene therapy using adenoviruses expressing thymidine kinase (TK) and fms-like tyrosine kinase 3 ligand (Flt3L). mACVR1 NS expressing the surrogate tumor antigen ovalbumin were generated to investigate if TK/Flt3L treatment induces the recruitment of tumor-antigen specific T cells. Results Histological analysis of mACVR1 tumors indicates that they are localized in the brainstem and have increased downstream signaling of bone morphogenetic pathway as demonstrated by increased phospho-smad1/5 and Id1 levels. Transcriptome analysis of mACVR1 NS identified an increase in the transforming growth factor beta (TGF-β) signaling pathway and the regulation of cell differentiation. Adenoviral delivery of TK/Flt3L in mice bearing brainstem gliomas resulted in anti-tumor immunity, recruitment of anti-tumor specific T cells and increased median survival. Conclusions This study provides insights into the phenotype and function of the tumor immune microenvironment in a mouse model of brainstem glioma harboring mACVR1. Immune stimulatory gene therapy targeting the hosts’ anti-tumor immune response inhibits tumor progression and increases median survival of mice bearing mACVR1 tumors. Translational Relevance The therapeutic efficacy of anti-DIPG immune responses is limited due to a low number of immune cells in the tumor microenvironment. We have uncovered a novel treatment strategy that utilizes adenoviral delivery of therapeutic genes, thymidine kinase (TK) and fms tyrosine kinase 3 ligand (Flt3L) into the tumor, eliciting a reprograming of the host’s own immune system to recognize and kill tumor cells. We demonstrate that TK/Flt3L therapy generates an effective anti-tumor response and can be safely delivered into the brainstem. This treatment approach could provide a novel translational approach towards potentiating an anti-DIPG immune response to overcome the current limitations in the treatment of patients with DIPG.

Tmic-51. Neuroimmune-Competent Organoid Modeling Of Microglia/Tumor Interactions And Drug Responsiveness

Tmic-34. Infiltrative Behavior Of Patient-Derived Glioblastoma Cell Lines In Region-Specific Human Brain Organoids

Tmod-28. Modeling Microenvironmental Dynamics: A Novel 3D Glioma-Neuron Fusion Model

DIPG-66. MULTIPLEXED IMMUNOFLUORESCENCE MAPPING AND AI MODEL PREDICTION OF TUMOR MICROENVIRONMENT IN DIFFUSE MIDLINE GLIOMAS

Tmic-33. Microenvironment-Driven Changes In Glioblastoma Cell State Signatures Examined Using Region-Specific Human Brain Organoids

Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids

Abstract IA016: Mapping microglia – tumor crosstalk in pediatric brain cancer

In silico Experimentation of Glioma Microenvironment Development and Anti-tumor Therapy

GlioME: A Novel Organoid Model Retaining the Glioma Mi-croenvironment for Personalized Drug Screening and Thera-peutic Evaluation

GLIOMA-14 ELUCIDATING THE CELL-CELL INTERACTIONS AND GEO-SPATIAL ORIENTATION OF M2 POLARIZED MACROPHAGES/MICROGLIA WITHIN GBM'S TME AND INVESTIGATING THEIR IMMUNOSUPPRESSIVE EFFECT ON DENDRITIC CELLS

OS10.5.A Modeling immunocompetent tumor microenvironment in glioblastoma patient-derived orthotopic xenografts

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

TMIC-61. INVESTIGATING REPROGRAMING OF THE GBM’S TUMOR MICROENVIRONMENT AS A RESULT OF CO-TRANSFER OF HEMATOPOIETIC STEM CELLS (HSCS) WITH ADOPTIVE CELLULAR THERAPY

Tmod-36. Nanoglios: A Miniaturized Patient Avatar Enabling Rapid And High-Throughput Phenotypic Screening For Gliomas

Tmod-31. Single-Cell Profiling And Characterization Of Patient-Derived Xenograft Glioblastoma Model In Humanized Mice

Spatial Transcriptomic Sequencing of a DIPG-infiltrated Brainstem reveals Key Invasion Markers and Novel Ligand-Receptor Pairs contributing to Tumour to TME Crosstalk

Immu-66. Physiologically Relevant Murine Glioma Models That Represent Gbm Heterogeneity And Enable The Next Generation Of Discovery And Therapy Efficacy Studies

Organoid Modeling of the Tumor Immune Microenvironment

A Tumorigenicity Evaluation Platform for Cell Therapies Based on Brain Organoids

Modeling Glioma Intratumoral Heterogeneity with Primary Human Neural Stem and Progenitor Cells